- Home
- SLDB
as 02-21-2025 4:00pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 124.7M | IPO Year: | 2018 |
| Target Price: | $17.83 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.88 - $15.05 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Feb 13 '25 | Sell | $3.96 | 3,079 | $12,192.84 | 19,281 | |
| Brooks Gabriel | SLDB | Chief Medical Officer | Feb 13 '25 | Sell | $3.96 | 3,256 | $12,893.76 | 22,812 | |
| Ganot Ilan | SLDB | Director | Feb 13 '25 | Sell | $3.96 | 1,711 | $6,775.56 | 14,839 | |
| Howton David T | SLDB | Chief Operating Officer | Feb 13 '25 | Sell | $3.96 | 5,561 | $22,021.56 | 24,789 | |
| Tan Kevin | SLDB | CFO & Treasurer | Feb 13 '25 | Sell | $3.96 | 3,164 | $12,529.44 | 32,250 | |
| Herzich Paul | SLDB | Chief Technology Officer | Feb 13 '25 | Sell | $3.96 | 2,688 | $10,644.48 | 18,388 | |
| Ganot Ilan | SLDB | Director | Jan 27 '25 | Sell | $3.11 | 144 | $447.78 | 14,839 | |
| Tan Kevin | SLDB | CFO & Treasurer | Jan 9 '25 | Sell | $3.89 | 4,073 | $15,849.26 | 32,250 | |
| Ganot Ilan | SLDB | Director | Jan 3 '25 | Sell | $4.31 | 1,056 | $4,551.36 | 14,839 | |
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Dec 2 '24 | Sell | $5.60 | 4,610 | $25,822.45 | 19,281 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Wedbush Adjusts Price Target on Solid Biosciences to $18 From $16, Keeps Outperform Rating
Zacks
3 days ago
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
Clinical Trials Arena
3 days ago
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
MT Newswires
4 days ago
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering
MT Newswires
4 days ago
Top Midday Gainers
GlobeNewswire
4 days ago
Solid Biosciences Announces Pricing of Underwritten Offering
GlobeNewswire
4 days ago
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
BioPharma Dive
4 days ago
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.